Zamann Pharma Support logo

Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Request an appointment now

CAPA Documentation in 2026: Step-by-Step Process, GMP Requirements, and Compliance Best Practices

This Article explains the structured CAPA workflow in quality management system, focusing on documentation elements required for GMP inspection readiness. It highlights how pharmaceutical teams ensure compliance through systematic deviation handling and controlled quality assurance processes.
  • Blog, Quality Management System
Circular diagram showing CAPA report format GMP elements including deviation record, root cause analysis pharmaceutical GMP, corrective actions, and effectiveness checks for audit readiness.

Why Quantum Chemistry Exposes AI’s Biggest Blind Spot; Drug Discovery Enters Validation Shock

A recent industry analysis by Loong Wang, fact-checked by Zachary Zubulake, highlights how quantum chemistry, pharmaceutical AI, and GPU-accelerated computing are converging to solve key limitations in drug discovery. The report shows that inconsistent experimental data and poor model interpretability
  • News
Why Quantum Chemistry Exposes AI’s Biggest Blind Spot; Drug Discovery Enters Validation Shock

Bristol Myers Expands AI Deal; Pharma Risks Falling Behind in Validation Race

Bristol Myers Squibb has expanded its collaboration with Anthropic to deploy the Claude AI system across multiple pharmaceutical functions, including research, manufacturing, quality monitoring, and regulatory workflows. The move reflects a broader industry shift toward AI-driven operations, but experts warn
  • News
Bristol Myers Expands AI Deal; Pharma Risks Falling Behind in Validation Race

Regulatory Affairs vs Quality Assurance in 2026: Key Differences, Roles, and Responsibilities in Pharmaceutical Industry

This article explains regulatory affairs responsibilities and quality assurance roles in pharma, highlighting how both functions interact within GMP inspection readiness pharma, data integrity in quality systems, CAPA deviation management pharma, and the overall regulatory compliance framework pharma.
  • Blog, Quality Management System
High-tech pharmaceutical laboratory illustrating regulatory affairs responsibilities and quality assurance roles in pharma, highlighting GMP inspection readiness pharma, data integrity in quality systems, and pharmaceutical quality governance system in compliance operations.

FDA Real-Time Clinical Trials; Hidden Risks Emerging That Few Are Seeing

The United States Food and Drug Administration (FDA) has launched a pilot program to enable real-time clinical trial data review, allowing safety signals and endpoints to reach regulators as data is recorded. In a discussion with Pharmaceutical Executive, Dr. Richard
  • News
FDA Real-Time Clinical Trials; Hidden Risks Emerging That Few Are Seeing

FDA vs EMA in 2026: Key Regulatory Differences, Approval Processes, and Compliance Requirements in Pharma Industry

This article explains key differences between FDA and EMA regulatory systems, focusing on approval processes, GMP inspection readiness, and compliance expectations. It also highlights data integrity compliance, pharmacovigilance requirements, and regulatory submission strategy for global pharmaceutical market authorization.
  • Blog, Quality Management System
Pharmaceutical compliance infographic showing FDA approval process and EMA approval process differences, including GMP inspection readiness, pharmacovigilance requirements, and regulatory submission strategy for global market authorization.

Agentic AI Increases Compliance Risk; Is Pharma Falling Behind on Validation?

Emerging biopharma companies are rapidly adopting agentic AI to automate workflows and connect decision-making across regulated environments. Industry discussions involving ZS and SynOx Therapeutics highlight this accelerating shift. However, experts warn that many organizations still lack validated infrastructure, strong data
  • News
Agentic AI Increases Compliance Risk; Is Pharma Falling Behind on Validation?

AstraZeneca and Roche Bet on Focused R&D; But Is Failure Risk Rising?

Big pharmaceutical companies are accelerating a shift toward highly specialized R&D strategies as they prepare for a wave of patent expirations and rising pricing pressure. In a PharmaVoice report published on May 20, 2026, industry leaders including, AstraZeneca and Roche,
  • News
AstraZeneca and Roche Bet on Focused R&D; But Is Failure Risk Rising?

EU Clinical Trials Hit 2030 Targets Progress, But Execution Gap Widens

The first quarterly CTIS report reveals that EU clinical trials are moving steadily toward their 2030 targets, but critical execution gaps remain unresolved. While trial volumes and regulatory processes appear stable across the EU and EEA, data highlights persistent weaknesses
  • News
EU Clinical Trials Hit 2030 Targets Progress, But Execution Gap Widens

GxP Regulations in 2026: GMP, GLP, GDP, and Compliance Standards in Pharmaceutical Quality Systems

Explore GxP compliance frameworks and regulatory expectations across GMP, GLP and GDP systems, focusing on data integrity in pharma, ALCOA principles, audit readiness, and risk-based validation strategies aligned with FDA regulatory compliance pharma and EMA GMP guidelines.
  • Blog, Quality Management System
Pharmaceutical quality system workflow illustrating audit readiness in the pharmaceutical industry, emphasizing data integrity in pharma, ALCOA data integrity principles, GMP inspection findings, and risk based validation pharma approaches under EMA GMP guidelines and FDA regulatory compliance pharma.